Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Agilent Reports Fourth-Quarter Results

Published: Monday, November 18, 2013
Last Updated: Monday, November 18, 2013
Bookmark and Share
Agilent Technologies reported orders up 4 percent over one year ago to $1.83 billion with revenues of $1.72 billion, down 3 percent compared with one year ago.

Fourth-quarter GAAP net income was $211 million, or $0.63 per share. Last year's fourth-quarter GAAP net income was $425 million, or $1.20 per share.

During the fourth quarter, Agilent had intangible amortization of $48 million, integration and transformation costs of $12 million, one-time separation costs of $5 million and a tax benefit of $9 million. Excluding these items and $4 million of other net charges, Agilent reported fourth-quarter adjusted net income of $271 million, or $0.81 per share(1).

Agilent CEO Bill Sullivan said, "We finished the year with a solid quarter, building backlog and exceeding EPS guidance despite challenges in several of our markets. This reflected our ongoing commitment to actively manage expenses and reduce manufacturing costs in a period of economic uncertainty.

"We are now well into the process of splitting Agilent into two companies, as we announced Sept. 19. We expect to complete the separation in early November 2014."

Electronic Measurement fourth-quarter revenues were down 14 percent compared with the prior year. Operating margins were 19 percent, reflecting solid gross margins and good management of spending in response to continuing challenges in the global economy.

Chemical Analysis revenues were up 4 percent compared with a year ago, led by growth in food and energy markets. Operating margins were 25 percent.

Life Sciences and Diagnostics revenues were up 8 percent over a year ago, with strength in pharmaceuticals and diagnostics markets. Operating margins were 19 percent.

Agilent generated $377 million of cash from operations in the quarter. Fourth-quarter ROIC was 17 percent(3).

First-quarter 2014 revenues are expected to be in the range of $1.68 billion to $1.70 billion. First-quarter non-GAAP earnings are expected to be in the range of $0.65 to $0.67 per share(2).

For the full fiscal year 2014, Agilent expects revenue of $6.95 billion to $7.15 billion and non-GAAP earnings of $3.03 to $3.33 per share(2).



Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,500+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Agilent, Singapore Institute Collaborate
Agilent Technologies and Singapore's Bioprocessing Technology Institute today announced a collaboration to develop new analytical approaches to specific protein-linked sugar compounds.
Wednesday, July 15, 2015
Agilent Collaborate with A*STAR’s Bioprocessing Technology Institute
Collaboration addresses a critical need in the biopharmaceutical industry.
Tuesday, July 14, 2015
Agilent Technologies and Waters Corporation Formalize Instrument Control Exchange
Agilent Technologies Inc. and Waters Corp have announced a formal agreement to exchange instrument controls to improve the productivity of customers who own software and instruments from both companies.
Wednesday, July 01, 2015
Agilent Technologies Launches New Products for Analyzing Biotherapeutics
Expanded AdvanceBio portfolio enables scientists to speed research and lower costs.
Thursday, June 25, 2015
Agilent to Focus on "Powerful Partnerships, Inspiring Results" at ASMS 2015
Company to introduce solutions enabling new standards in mass spectrometry, lab productivity.
Friday, May 29, 2015
Agilent Announces New CEO Mike McMullen
McMullen elected as chief executive officer by Company’s board of directors.
Thursday, March 19, 2015
Agilent’s Microarray Scanner Approved for In Vitro Diagnostics in China
Regulators approve SureScan Dx as medical device.
Wednesday, January 28, 2015
Utilizing Fast HPLC Screening Methods for the Detection of Steroids
Analysis of steroids improved by choosing the optimal HPLC column for the separation.
Saturday, January 17, 2015
Agilent Names Alacris Theranostics as Certified Provider of Target Enrichment Services
Customers receive consistent data quality, reproducibility and reliability.
Saturday, January 17, 2015
Benefits of SPE for the Analysis of Mycotoxins
Fast and cost-effective sample preparation is essential for the analysis of mycotoxins in food and feed.
Wednesday, January 14, 2015
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent Technologies - Making Better GC Connections
Improving GC connections for reliable, robust and reproducible results.
Wednesday, December 24, 2014
How to Achieve High-Speed, High-Resolution Glycan Mapping for mAb Characterization
The full characterization of biotherapeutics is required by regulatory authorities as properties such as safety, efficacy and the serum half-life of therapeutic proteins can be affected by differences in their glycosylation pattern.
Monday, December 22, 2014
Agilent, Baylor Open Mass Spec Center of Excellence
The new facility aims to boost metabolomics research at Baylor College of Medicine.
Friday, December 05, 2014
Agilent, MRM Proteomics Extend Agreement
Agreement expands on an existing collaboration established in 2012, allowing both organizations to bolster their combined proteomics solutions, comprising reagent kits, hardware and software.
Friday, July 25, 2014
Scientific News
Liquid Biopsies: Utilization of Circulating Biomarkers for Minimally Invasive Diagnostics Development
Market Trends in Biofluid-based Liquid Biopsies: Deploying Circulating Biomarkers in the Clinic. Enal Razvi, Ph.D., Managing Director, Select Biosciences, Inc.
Lab-on-a-Chip Offers Promise for TB and Asthma Patients
A device to mix liquids using ultrasonics is the first and most difficult component in a miniaturized system for low-cost analysis of sputum from patients with pulmonary diseases such as tuberculosis and asthma.
Intracellular Microlasers Could Allow Precise Labeling of up to a Trillion Individual Cells
MGH investigators have induced structures incorporated within individual cells to produce laser light at wavelengths that differ based on the size, shape and composition of each microlaser, allowing precise labeling of individual cells.
Real-Time Imaging of Lung Lesions During Surgery
Targeted molecular agents cause lung adenocarcinomas to fluoresce during surgery, according to pilot report.
Watching a Tumour Grow in Real-Time
Researchers from the University of Freiburg have gained new insight into the phases of breast cancer growth.
Protein Related to Long Term Traumatic Brain Injury Complications Discovered
NIH-study shows protein found at higher levels in military members who have suffered multiple TBIs.
Childhood Cancer Cells Drain Immune System’s Batteries
Cancer cells in neuroblastoma contain a molecule that breaks down a key energy source for the body’s immune cells, leaving them too physically drained to fight the disease.
Urine Proteins Point to Early-Stage Pancreatic Cancer
A combination of three proteins found at high levels in urine can accurately detect early-stage pancreatic cancer, researchers at the BCI have shown.
Researcher Discovers Trigger of Deadly Melanoma
New research sheds light on the precise trigger that causes melanoma cancer cells to transform from non-invasive cells to invasive killer agents, pinpointing the precise place in the process where "traveling" cancer turns lethal.
New Vaccine For Chlamydia to Use Synthetic Biology
Prokarium Ltd, a biotechnology company developing transformational oral vaccines, have announced new funding from SynbiCITE, the UK’s Innovation and Knowledge Centre for Synthetic Biology.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!